Skip to main content

Table 3 Frequency and percentage of adverse events in the subset of patients with at least one adverse event and serious adverse event by body system, and COSTART term

From: Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial

Body System
/COSTART
No. (%) of events
  Ezetimibe (n = 18) Statin (n = 16)
Body as a Whole   
 Fever 1 (5.6) 0
 Headache 1 (5.6) 1 (6.3)
 Pain back 1 (5.6) 0
 Pain chest 1 (5.6) 0
Cardiovascular System   
 Syncope 0 1 (6.3)
Digestive System   
 Esophagitis 1 (5.6) 0
 Nausea 1 (5.6) 1 (6.3)
 Rectal discharge 1 (5.6) 0
Metabolic and Nutritional Disorders   
 Diabetes mellitus 1 (5.6) 0
 Gout 1 (5.6) 0
Nervous System   
 Anxiety 1 (5.6) 0
 Dizziness 2 (11.1) 1 (6.3)
 Insomnia 0 1 (6.3)
 Vertigo 0 3 (18.8)
Respiratory System   
 Cough inc 0 1 (6.3)
 Pharyngitis 3* (16.6) 1 (6.3)
 Rhinitis 0 1 (6.3)
 Sputum inc 0 1 (6.3)
 Voice altered 0 1 (6.3)
Skin and Appendages   
 Rash 1 (5.6) 0
Special Senses   
 Cataract 1 (5.6) 0
 Conjunctivitis 1 (5.6) 1 (6.3)
 Deaf 0 1 (6.3)
 Tinnitus 0 1 (6.3)
  1. * One Serious Adverse Event.